Market Research

Insulin Delivery Devices Market Size, Share & Trends Analysis Report By Product (Reusable Insulin Pens, Disposable Insulin Pens), By End Use (Hospitals & Clinics, Homecare), By Region, And Segment Forecasts, 2024 - 2030

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 150 Pages Grand View Research July, 2024 GV19065643
Best Price Guarantee
Price from $5,950
Length 150 Pages
Publisher Grand View Research
Published Date July, 2024
SKU GV19065643

Insulin Delivery Devices Market Size, Share & Trends Analysis Report By Product (Reusable Insulin Pens, Disposable Insulin Pens), By End Use (Hospitals & Clinics, Homecare), By Region, And Segment Forecasts, 2024 - 2030


Insulin Delivery Devices Market Growth & Trends

The global insulin delivery devices market size was estimated at USD 28.06 billion in 2030 and is expected to grow at a CAGR of 7.89% from 2024 to 2030. Obesity, sedentary lifestyles, and unhealthy food habits, primarily in the young population, lead to the occurrence of diabetes. In addition, the growing diabetic geriatric population is another factor supporting the growth of this vertical. According to the United Nations, Department of Economic and Social Affairs, around 901 million individuals were aged 60 or over in 2015 and this number is projected to increase to 1.4 billion by 2030. Thus, the enlarging elderly population is expected to boost the demand for insulin delivery devices.

Technological innovations and advancements are an ongoing trend in this vertical. The high demand for advanced insulin delivery devices is supporting the adoption of recently launched innovative pen devices and portable pumps, which is estimated to boost the market growth. Also, favorable reimbursement policies for these devices, mainly in developed countries like the U.S. and Germany, are anticipated to fuel the market growth during the study period. However, stringent regulatory requirements regulating the approval of insulin delivery devices and the high cost of insulin analogs in diabetes care management are major factors restraining the growth of this industry.

The market's prominent competitors are taking different initiatives such as acquisition, funding, and product development to expand their product portfolio and enhance their manufacturing capacity. For instance, in October 2021, Eli Lilly partnered with Cipla, to market its Insulin products (Humalog and Trulicity) in India. Additionally, In June 2021, the company acquired Protomer Technologies, to strengthen its market presence. Further, Novo Nordisk, joined hands with Biocorp to develop a Bluetooth-enabled smart add-on device for their pen insulin injector.

Insulin Delivery Devices Market Report Highlights
  • The insulin pens segment was the largest revenue-generating category of this market in 2021. The pen is equipped with self-contained cartridges and offers ease in handling and less pain while injecting insulin. The advantages of these pen devices over other products are resulting in their growing popularity, thus serving as a vital factor in contributing to the sectorb s highest share in this market
  • The home care segment is estimated to be the fastest-growing segment due to increased adoption of self-care diabetes management devices and the availability of simplified and user-friendly product designs for patients
  • North America is the leading regional sector and accounted for the largest revenue share in 2021 primarily due to the favorable reimbursement scenario in this space. Also, the presence of major manufacturers in this region is supporting market growth
  • In Asia Pacific, the market is anticipated to grow fast during the forecast period. The high prevalence rate of diabetes in countries, such as China and India, is a major factor contributing to market expansion in this region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Insulin Delivery Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rise in the prevalence of diabetes globally
3.2.1.2. Increasing geriatric population
3.2.1.3. Favorable government reimbursement scenario
3.2.1.4. Increasing awareness about diabetes preventive care
3.2.2. Market restraint analysis
3.2.2.1. Stringent regulatory framework
3.2.2.2. High cost of devices
3.3. Insulin Delivery Devices Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Insulin Delivery Devices Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Insulin Delivery Devices Product Market Movement Analysis
4.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Insulin Pens
4.4.1. Insulin pens market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Reusable Insulin Pens
4.4.2.1. Reusable insulin pens market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Disposable Insulin Pens
4.4.3.1. Disposable insulin pens market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Insulin Pumps
4.5.1. Insulin pumps market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Patch Pumps
4.5.2.1. Patch pumps market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Tethered Pumps
4.5.3.1. Tethered pumps market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Insulin Pen Needles
4.6.1. Insulin pen needles market estimates and forecasts 2018 to 2030 (USD Million)
4.6.2. Standard Pen Needles
4.6.2.1. Standard pen needles market estimates and forecasts 2018 to 2030 (USD Million)
4.6.3. Safety Pen Needles
4.6.3.1. Safety pen needles market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Insulin Syringes
4.8. Other Products
Chapter 5. Insulin Delivery Devices Market: End Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Insulin Delivery Devices End Use Market Movement Analysis
5.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Hospitals & Clinics
5.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Homecare
5.5.1. Homecare market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Other End User
5.6.1. Other End Users market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Insulin Delivery Devices Market: Regional Estimates & Trend Analysis By Product, End Use
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Competitive scenario
6.5.1.3. Regulatory framework
6.5.1.4. Reimbursement structure
6.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Competitive scenario
6.5.2.3. Regulatory framework
6.5.2.4. Reimbursement structure
6.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key country dynamics
6.5.3.2. Competitive scenario
6.5.3.3. Regulatory framework
6.5.3.4. Reimbursement structure
6.5.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Competitive scenario
6.6.1.3. Regulatory framework
6.6.1.4. Reimbursement structure
6.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Competitive scenario
6.6.2.3. Regulatory framework
6.6.2.4. Reimbursement structure
6.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Competitive scenario
6.6.3.3. Regulatory framework
6.6.3.4. Reimbursement structure
6.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Competitive scenario
6.6.4.3. Regulatory framework
6.6.4.4. Reimbursement structure
6.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Competitive scenario
6.6.5.3. Regulatory framework
6.6.5.4. Reimbursement structure
6.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Competitive scenario
6.6.6.3. Regulatory framework
6.6.6.4. Reimbursement structure
6.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Competitive scenario
6.6.7.3. Regulatory framework
6.6.7.4. Reimbursement structure
6.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Competitive scenario
6.6.8.3. Regulatory framework
6.6.8.4. Reimbursement structure
6.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Competitive scenario
6.7.1.3. Regulatory framework
6.7.1.4. Reimbursement structure
6.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Competitive scenario
6.7.2.3. Regulatory framework
6.7.2.4. Reimbursement structure
6.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Competitive scenario
6.7.3.3. Regulatory framework
6.7.3.4. Reimbursement structure
6.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Competitive scenario
6.7.4.3. Regulatory framework
6.7.4.4. Reimbursement structure
6.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Competitive scenario
6.7.5.3. Regulatory framework
6.7.5.4. Reimbursement structure
6.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Competitive scenario
6.7.6.3. Regulatory framework
6.7.6.4. Reimbursement structure
6.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Competitive scenario
6.8.1.3. Regulatory framework
6.8.1.4. Reimbursement structure
6.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Argentina
6.8.2.1. Key country dynamics
6.8.2.2. Competitive scenario
6.8.2.3. Regulatory framework
6.8.2.4. Reimbursement structure
6.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Competitive scenario
6.9.1.3. Regulatory framework
6.9.1.4. Reimbursement structure
6.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Competitive scenario
6.9.2.3. Regulatory framework
6.9.2.4. Reimbursement structure
6.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Competitive scenario
6.9.3.3. Regulatory framework
6.9.3.4. Reimbursement structure
6.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Competitive scenario
6.9.4.3. Regulatory framework
6.9.4.4. Reimbursement structure
6.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Key company market share analysis, 2023
7.4. Company Position Analysis
7.5. Company Categorization (Emerging Players, Innovators and Leaders
7.6. Company Profiles
7.6.1. Novo Nordisk A/S
7.6.1.1. Company overview
7.6.1.2. Financial performance
7.6.1.3. Product benchmarking
7.6.1.4. Strategic initiatives
7.6.2. Sanofi
7.6.2.1. Company overview
7.6.2.2. Financial performance
7.6.2.3. Product benchmarking
7.6.2.4. Strategic initiatives
7.6.3. Eli Lilly and Company
7.6.3.1. Company overview
7.6.3.2. Financial performance
7.6.3.3. Product benchmarking
7.6.3.4. Strategic initiatives
7.6.4. Ypsomed AG
7.6.4.1. Company overview
7.6.4.2. Financial performance
7.6.4.3. Product benchmarking
7.6.4.4. Strategic initiatives
7.6.5. Medtronic
7.6.5.1. Company overview
7.6.5.2. Financial performance
7.6.5.3. Product benchmarking
7.6.5.4. Strategic initiatives
7.6.6. Insulet Corporation
7.6.6.1. Company overview
7.6.6.2. Financial performance
7.6.6.3. Product benchmarking
7.6.6.4. Strategic initiatives
7.6.7. B. Braun SE
7.6.7.1. Company overview
7.6.7.2. Financial performance
7.6.7.3. Product benchmarking
7.6.7.4. Strategic initiatives
7.6.8. Owen Mumford Ltd.
7.6.8.1. Company overview
7.6.8.2. Financial performance
7.6.8.3. Product benchmarking
7.6.8.4. Strategic initiatives
7.6.9. Tandem Diabetes Care, Inc.
7.6.9.1. Company overview
7.6.9.2. Financial performance
7.6.9.3. Product benchmarking
7.6.9.4. Strategic initiatives
7.6.9.5. Company overview
7.6.10. BD
7.6.10.1. Company overview
7.6.10.2. Financial performance
7.6.10.3. Product benchmarking
7.6.10.4. Strategic initiatives
7.6.10.5. Company overview

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings